A large-scale genomic study of 203 multiple myeloma (MM) patients revealed widespread genetic heterogeneity, with significant mutations in genes such as KRAS, NRAS, BRAF, FAM46C, TP53, and DIS3. These mutations were often present in subclonal populations, and multiple mutations within the same pathway were observed in the same patient. The study identified recurrently mutated genes and highlighted the importance of clonal heterogeneity in MM, which may affect treatment outcomes. Mutations in genes like PRDM1 and EGR1 were found to be associated with somatic hypermutation, suggesting a role in MM pathogenesis. The study also identified tumor suppressor genes such as CDKN2C, TRAF3, BIRC2, BIRC3, and CYLD, which were frequently mutated. The results emphasize the need for comprehensive analysis of clonal heterogeneity to guide targeted therapy. The study found that clonal heterogeneity is common in MM, with many patients harboring multiple subclones. The presence of subclonal mutations may limit the effectiveness of targeted therapies, as treatments targeting subclonal mutations may not affect all tumor cells. The study also showed that BRAF mutations may be clonal or subclonal, and that targeting BRAF mutations may not be effective in all cases. The findings suggest that combination therapies targeting multiple pathways may be more effective in treating MM. The study highlights the importance of understanding the genetic diversity of MM to develop effective targeted therapies.A large-scale genomic study of 203 multiple myeloma (MM) patients revealed widespread genetic heterogeneity, with significant mutations in genes such as KRAS, NRAS, BRAF, FAM46C, TP53, and DIS3. These mutations were often present in subclonal populations, and multiple mutations within the same pathway were observed in the same patient. The study identified recurrently mutated genes and highlighted the importance of clonal heterogeneity in MM, which may affect treatment outcomes. Mutations in genes like PRDM1 and EGR1 were found to be associated with somatic hypermutation, suggesting a role in MM pathogenesis. The study also identified tumor suppressor genes such as CDKN2C, TRAF3, BIRC2, BIRC3, and CYLD, which were frequently mutated. The results emphasize the need for comprehensive analysis of clonal heterogeneity to guide targeted therapy. The study found that clonal heterogeneity is common in MM, with many patients harboring multiple subclones. The presence of subclonal mutations may limit the effectiveness of targeted therapies, as treatments targeting subclonal mutations may not affect all tumor cells. The study also showed that BRAF mutations may be clonal or subclonal, and that targeting BRAF mutations may not be effective in all cases. The findings suggest that combination therapies targeting multiple pathways may be more effective in treating MM. The study highlights the importance of understanding the genetic diversity of MM to develop effective targeted therapies.